Ignite Creation Date:
2025-12-25 @ 5:03 AM
Ignite Modification Date:
2025-12-26 @ 4:05 AM
Study NCT ID:
NCT05306418
Status:
COMPLETED
Last Update Posted:
2025-11-13
First Post:
2022-03-23
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 70}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2022-04-04', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'dispFirstSubmitDate': '2025-11-11', 'completionDateStruct': {'date': '2024-11-13', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-11-11', 'studyFirstSubmitDate': '2022-03-23', 'studyFirstSubmitQcDate': '2022-03-23', 'dispFirstPostDateStruct': {'date': '2025-04-11', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2025-11-13', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2022-04-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-11-13', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of treatment emergent adverse events', 'timeFrame': 'From treatment initiation to follow up visit (week 0 to week 72)', 'description': 'Count of events'}], 'secondaryOutcomes': [{'measure': 'Number of treated bleeds', 'timeFrame': 'From treatment initiation to end of treatment (week 0 to week 52)', 'description': 'Count of bleeds'}, {'measure': 'Number of treated spontaneous bleeds', 'timeFrame': 'From treatment initiation to end of treatment (week 0 to week 52)', 'description': 'Count of bleeds'}, {'measure': 'Number of treated traumatic bleeds', 'timeFrame': 'From treatment initiation to end of treatment (week 0 to week 52)', 'description': 'Count of bleeds'}, {'measure': 'Number of treated joint bleeds', 'timeFrame': 'From treatment initiation to end of treatment (week 0 to week 52)', 'description': 'Count of bleeds'}, {'measure': 'Number of treated target joint bleeds', 'timeFrame': 'From treatment initiation to end of treatment (week 0 to week 52)', 'description': 'Count of bleeds'}, {'measure': 'Number of injection site reactions', 'timeFrame': 'From treatment initiation to end of treatment (week 0 to week 52)', 'description': 'Count of reactions'}, {'measure': 'Consumption of factor product per bleed treatment (number of injections)', 'timeFrame': 'From run-in initiation to end of treatment (week -26 to week 52)', 'description': 'Count of injections'}, {'measure': 'Occurrence of anti-Mim8 antibodies', 'timeFrame': 'From treatment initiation to end of treatment (week 0 to week 52)', 'description': 'Count of participants'}, {'measure': 'Mim8 plasma concentration', 'timeFrame': 'From treatment initiation to end of treatment (week 0 to week 52)', 'description': 'µg/mL'}, {'measure': 'Change in physical function domain of PEDS QL (Paediatric Quality of Life inventory) Generic Core Scales', 'timeFrame': 'From treatment initiation to end of treatment (week 0 to week 52)', 'description': 'Score on a scale 0-100 (applies for scale scores and total score). A higher score indicates a better health-related quality of life'}, {'measure': 'Treatment preference for Mim8 versus previous treatment using Caregiver H PPQ (Caregiver Haemophilia Patient Preference )', 'timeFrame': 'Once during treatment (week 26)', 'description': 'Percentage of participants'}, {'measure': "Change in participants' treatment burden using the Hemo TEM (Haemophilia treatment experience measure)", 'timeFrame': 'From treatment initiation to end of treatment (week 0 to week 52)', 'description': 'Score on a scale 0-100 (applies for scale scores and total score). A lower score indicates a lower treatment burden.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Haemophilia A With or Without Inhibitors']}, 'descriptionModule': {'briefSummary': 'This study is looking at how Mim8 works compared to other medicines in children with haemophilia A, who either have inhibitors or do not have inhibitors.\n\nMim8 is a new medicine that will be used for prevention of bleeds. Mim8 will be injected with a thin needle into the skin. The study will last for about 54-98 weeks, from screening to follow-up visit, In case the participant experiences bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '11 Years', 'minimumAge': '1 Year', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n2. Male and female participants with the diagnosis of congenital haemophilia A of any severity based on medical records.\n3. Aged 1-11 years (both inclusive) at the time of signing informed consent.\n4. For previously treated participants :\n\n 1. Participant has been prescribed treatment with FVIII concentrate or bypassing agent in the last 26 weeks prior to screening.\n 2. Participants with endogenous FVIII activity greater than or equal to 1%, based on medical records, must have at least 1 treated bleed during the previous 26 weeks before screening for which factor VIII concentrate or bypassing agent has been prescribed (no requirements for participants with FVIII activity below 1%).\n5. For previously untreated participants:\n\n a. Diagnosis of severe haemophilia A (endogenous FVIII activity below 1%) based on medical records.\n6. Child and parent/caregiver willingness and ability to comply with scheduled visits and study procedures, including the completion of diary and patient-reported outcomes questionnaires.( For China mainland; assessed at the investigator's discretion unless otherwise stated.)\n\nExclusion criteria:\n\n1. Known or suspected hypersensitivity to trial product or related products.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)\n2. Previous participation in this study. Participation is defined as signed informed consent.\n3. Participation (i.e., signed informed consent) in any interventional clinical study with receipt of last dose within 6 months (or 5 half-lives of the investigational medicinal product, whichever is shorter) before planned randomisation.\n4. Exposure to non-factor haemostatic products for bleeding prophylaxis within 6 months (or 5 half-lives of the medicinal product, whichever is shorter) before planned randomisation, for participants not included in the run-in.\n5. Known congenital or acquired coagulation disorders other than haemophilia A.\n6. Other conditions (e.g. autoimmune disease) or laboratory abnormality that may increase risk of bleeding or thrombosis, as evaluated by the investigator.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)\n7. Any disorder, except for conditions associated with haemophilia A, that in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)\n8. Mental incapacity, unwillingness to cooperate or a language barrier precluding adequate understanding and cooperation.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)\n9. Lack of adequate parental/caregiver support to enter accurately and timely information regarding treatment and bleeding episodes into an (electronic) diary.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)\n10. Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease.\n11. Major surgery planned to take place after screening.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)\n12. Immune tolerance induction planned to take place after treatment initiation.(For China mainland; assessed at the investigator's discretion unless otherwise stated.)\n13. Hepatic dysfunction defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) greater than 3 times the upper limit of normal combined with total bilirubin greater than 1.5 times the upper limit of normal measured at screening.\n14. Serum creatinine above 1.5 x upper limit of normal (ULN), measured at screening.\n15. Pregnancy (female participants).(Will be assessed at investigator's discretion, according to suspicion of pregnancy.)"}, 'identificationModule': {'nctId': 'NCT05306418', 'briefTitle': 'A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors', 'organization': {'class': 'INDUSTRY', 'fullName': 'Novo Nordisk A/S'}, 'officialTitle': 'Safety, Efficacy and Exposure of Subcutaneously Administered NNC0365-3769 (Mim8) Prophylaxis in Children With Haemophilia A With or Without FVIII Inhibitors', 'orgStudyIdInfo': {'id': 'NN7769-4516'}, 'secondaryIdInfos': [{'id': 'U1111-1255-1540', 'type': 'OTHER', 'domain': 'World Health Organization (WHO'}, {'id': '2020-003467-26', 'type': 'EUDRACT_NUMBER'}, {'id': 'jRCT2031220670', 'type': 'REGISTRY', 'domain': 'jRCT'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Mim8', 'description': '52-week treatment period with a part 1 and part 2, where all participants receive Mim8 prophylaxis', 'interventionNames': ['Drug: Mim8']}], 'interventions': [{'name': 'Mim8', 'type': 'DRUG', 'description': 'For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.\n\nMim8 will be injected with a thin needle into the skin', 'armGroupLabels': ['Mim8']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90027', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': "Children's Hospital Los Angeles - Endocrinology", 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'country': 'United States', 'facility': 'Univ of Colorado Sch of Med', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '33607', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': "St Joseph's Hospital Foundation", 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '30322', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': "Children's Healthcare Atlanta", 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '31404', 'city': 'Savannah', 'state': 'Georgia', 'country': 'United States', 'facility': "Children's Hospital at Memorial Health", 'geoPoint': {'lat': 32.08354, 'lon': -81.09983}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'country': 'United States', 'facility': 'University of Iowa_Iowa City', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '44106', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'Univ Hosp Cleveland Med Ctr', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '17033-2360', 'city': 'Hershey', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Penn State MS Hershey Med Ctr', 'geoPoint': {'lat': 40.28592, 'lon': -76.65025}}, {'zip': '19134', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'St Christopher Hosp for Child', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': 'L8N 3Z5', 'city': 'Hamilton', 'state': 'Ontario', 'country': 'Canada', 'facility': "McMaster Children's Hospital", 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'zip': 'M5G 1X8', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'The Hospital for Sick Children', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': '100045', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': "Beijing Children's Hospital, Capital Medical University", 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '100045', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': "Beijing Children's Hospital，Capital Medical University", 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '510515', 'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'facility': 'Nanfang Hospital, Southern Medical University-Haematology', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '610000', 'city': 'Chengdu', 'state': 'Sichuan', 'country': 'China', 'facility': "Chengdu Women's and Children's Central Hospital", 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '300020', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'country': 'China', 'facility': 'Institute of Hematology and Blood Diseases Hospital, Tianjin-Hematology', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'zip': '310052', 'city': 'Hangzhou', 'state': 'Zhejiang', 'country': 'China', 'facility': "Children's Hospital, Zhejiang University School of Medicine", 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '53127', 'city': 'Bonn', 'country': 'Germany', 'facility': 'Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie', 'geoPoint': {'lat': 50.73438, 'lon': 7.09549}}, {'zip': '395002', 'city': 'Surat', 'state': 'Gujarat', 'country': 'India', 'facility': 'Nirmal Hospital Pvt. Ltd.', 'geoPoint': {'lat': 21.19594, 'lon': 72.83023}}, {'zip': '400012', 'city': 'Mumbai', 'state': 'Maharashtra', 'country': 'India', 'facility': 'Seth GS Medical College & KEM Hospital', 'geoPoint': {'lat': 19.07283, 'lon': 72.88261}}, {'zip': '411004', 'city': 'Pune', 'state': 'Maharashtra', 'country': 'India', 'facility': 'Sahyadri Super Speciality Hospital', 'geoPoint': {'lat': 18.51957, 'lon': 73.85535}}, {'zip': '302004', 'city': 'Jaipur', 'state': 'Rajasthan', 'country': 'India', 'facility': 'J K Lon Hospital', 'geoPoint': {'lat': 26.91962, 'lon': 75.78781}}, {'zip': '201303', 'city': 'Noida', 'state': 'Uttar Pradesh', 'country': 'India', 'facility': 'Post Graduate Institute of Child Health', 'geoPoint': {'lat': 28.58, 'lon': 77.33}}, {'zip': '52621', 'city': 'Tel Litwinsky', 'country': 'Israel', 'facility': 'Sheba MC - The Israeli National Hemophilia Center', 'geoPoint': {'lat': 32.05096, 'lon': 34.84588}}, {'zip': '00165', 'city': 'Rome', 'country': 'Italy', 'facility': 'Ospedale Pediatrico Bambino Ges', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '10126', 'city': 'Torino', 'country': 'Italy', 'facility': 'A.O.U. Città della Salute e della Scienza di Torino-Ospedale', 'geoPoint': {'lat': 44.88856, 'lon': 11.99138}}, {'zip': '373-8585', 'city': 'Gunma', 'country': 'Japan', 'facility': 'Ota Memorial Hospital_Pediatrics'}, {'zip': '004-0041', 'city': 'Hokkaido', 'country': 'Japan', 'facility': 'Sapporo Tokushukai Hospital_Pediatrics'}, {'zip': '330-8777', 'city': 'Saitama', 'country': 'Japan', 'facility': "Saitama Children's Med Centre_Hematology-Oncology", 'geoPoint': {'lat': 35.90807, 'lon': 139.65657}}, {'zip': '167-0035', 'city': 'Tokyo', 'country': 'Japan', 'facility': 'Ogikubo Hospital_Pediatries & Blood', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'zip': '08406', 'city': 'Vilnius', 'country': 'Lithuania', 'facility': "Children Oncohaematology department Children's Hospital,", 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': '1105 AZ', 'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'Academisch Medisch Centrum', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '3584 CX', 'city': 'Utrecht', 'country': 'Netherlands', 'facility': 'UMC Utrecht, Van Creveldkliniek', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}, {'zip': '50-556', 'city': 'Wroclaw', 'state': 'Lower Silesian Voivodeship', 'country': 'Poland', 'facility': 'Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '91-738', 'city': 'Lodz', 'country': 'Poland', 'facility': 'CSK UM Uniwersyteckie Centrum Pediatrii im. M. Konopnickiej', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '20-093', 'city': 'Lublin', 'country': 'Poland', 'facility': 'Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '1169-045', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Unidade Local de Saúde São José EPE- Hospital D. Estefânia', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '4200-319', 'city': 'Porto', 'country': 'Portugal', 'facility': 'ULS São João, E.P.E.', 'geoPoint': {'lat': 41.1485, 'lon': -8.61097}}, {'zip': '650066', 'city': 'Kemerovo', 'country': 'Russia', 'facility': 'SAHI Kuzbass Hospital(former Regional clinical hospital)', 'geoPoint': {'lat': 55.35417, 'lon': 86.10435}}, {'zip': '350007', 'city': 'Krasnodar', 'country': 'Russia', 'facility': 'Children Regional Clinical Hospital', 'geoPoint': {'lat': 45.04534, 'lon': 38.98178}}, {'zip': '119049', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Morozovskaya municipal children hospital', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '185019', 'city': 'Petrozavodsk', 'country': 'Russia', 'facility': 'Republican Hospital n.a. V. A. Baranov', 'geoPoint': {'lat': 61.78491, 'lon': 34.34691}}, {'zip': '2193', 'city': 'Parktown, Johannesburg', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'Charlotte Maxeke Johannesburg Academic Hospital'}, {'zip': '35233', 'city': 'Daejeon', 'country': 'South Korea', 'facility': 'Daejeon Eulji Medical Center, Eulji University', 'geoPoint': {'lat': 36.34913, 'lon': 127.38493}}, {'zip': '03722', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Severance Hospital, Yonsei University Health System', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '08950', 'city': 'Esplugues Llobregat', 'country': 'Spain', 'facility': 'Hospital Sant Joan de Déu'}, {'zip': '28046', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario La Paz', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '3010', 'city': 'Bern', 'country': 'Switzerland', 'facility': 'Universitätsklinik für Kinderheilkunde', 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}, {'zip': '6000', 'city': 'Lucerne', 'country': 'Switzerland', 'facility': 'Pädiatrische Onkologie-Hämatologie', 'geoPoint': {'lat': 47.05048, 'lon': 8.30635}}, {'zip': '100', 'city': 'Taipei', 'country': 'Taiwan', 'facility': "National Taiwan University Children's Hospital", 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': 'CF14 4XW', 'city': 'Cardiff', 'country': 'United Kingdom', 'facility': 'Arthur Bloom Haemophilia Centre', 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'zip': 'SE1 7EH', 'city': 'London', 'country': 'United Kingdom', 'facility': "St Thomas' Hospital - Haemostasis and Thrombosis Centre", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}], 'overallOfficials': [{'name': 'Clinical Transparency (dept. 2834)', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Novo Nordisk A/S'}]}, 'ipdSharingStatementModule': {'url': 'http://novonordisk-trials.com', 'ipdSharing': 'YES', 'description': 'According to the Novo Nordisk disclosure commitment on novonordisk-trials.com'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}